Online inquiry

IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12681MR)

This product GTTS-WQ12681MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FZD1&FZD2&FZD5&FZD7&FZD8 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003505.2; NM_001466.4; NM_003468.4; NM_003507; NM_031866.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8321; 2535; 7855; 8324; 8325
UniProt ID Q9UP38; Q14332; Q13467; O75084; Q9H461
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12681MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6502MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ14372MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ12855MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ11204MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ11442MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ849MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ15492MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ14471MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO-7105705
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW